Skip to main content
SpringerLink
Log in

Medical Therapy for Heart Failure

  • Chapter
  • First Online:
Book cover Device Therapy in Heart Failure

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 905 Accesses

Abstract

Heart failure due to a decline in cardiac performance initiates compensatory neurohormonal mechanisms in an effort to maintain systemic perfusion. Ongoing neurohormonal activation may have deleterious consequences for cardiac performance, ventricular remodeling, myocardial function, and heart failure progression. The fundamental objective of modern medical therapy for heart failure is to relieve symptoms (largely through relief of volume overload) and to stall (or even reverse) disease progression through combined utilization of neurohormonal antagonists that help to restore normal hemodynamics, maintain normal plasma volume, and prevent ventricular enlargement. This chapter focuses on the key elements of medical therapy for heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Eichhorn EJ, Gheorghiade M. Digoxin – new perspective on an old drug. N Engl J Med 2002;347:1394–1395.

    PubMed  Google Scholar 

  2. Bristow MR, Linas S, Port JD. Drugs in the treatment of heart failure. In: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., vol. 1. Philadelphia: Elsevier Saunders, 2005:569–602.

    Google Scholar 

  3. Smith TW. Digoxin in heart failure. N Engl J Med 1993;329:51–53.

    CAS  PubMed  Google Scholar 

  4. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawl of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1–7.

    CAS  PubMed  Google Scholar 

  5. Garg R, Gorlin R, Smith T, Yusuf S. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.

    Google Scholar 

  6. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871–878.

    CAS  PubMed  Google Scholar 

  7. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403–1411.

    CAS  PubMed  Google Scholar 

  8. Adams KF, Patterson H, Gattis WA, O’Connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial. J Am Coll Cardiol 2005;46:497–504.

    CAS  PubMed  Google Scholar 

  9. Slatton ML, Irani WN, Hall SA, Marcoux LG, Page RL, Grayburn PA, Eichhorn EJ. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol 1997;29:1206–1213.

    CAS  PubMed  Google Scholar 

  10. Adams KF, Gheorghiade M, Uretsky BF, Young JB, Ahmed S, Tomasko L, Packer M. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol 1997;30:42–48.

    PubMed  Google Scholar 

  11. Hunt S, Abraham W, Chin M, et al., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2005;112:154–235.

    Google Scholar 

  12. Greger R. New insights into the molecular mechanisms of the action of diuretics. Nephrol Dial Transplant 1999;14:536–540.

    CAS  Google Scholar 

  13. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387–395.

    CAS  PubMed  Google Scholar 

  14. Pickkers P, Dormans TP, Russel FG, Hughes AD, Thien T, Schaper N, Smits P. Direct vascular effects of furosemide in humans. Circulation 1997;96:1847–52.

    CAS  PubMed  Google Scholar 

  15. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006;97:1759–1764.

    CAS  PubMed  Google Scholar 

  16. Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M; PRAISE Investigators. Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31–38.

    PubMed  Google Scholar 

  17. Cosin J, Diez J; TORIC investigators. Torsemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002;4:507–13.

    CAS  PubMed  Google Scholar 

  18. Costanzo M, Guglin M, Saltzberg M, Jessup M, Bart B, Teerlink J, Jaski B, Fang J, Feller E, Haas G, Anderson A, Schollmeyer M, Sobotka P; UNLOAD Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007 Feb 13;49:675–83.

    CAS  PubMed  Google Scholar 

  19. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagnoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH; Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000 Jul 27;343(4):246–53.

    CAS  PubMed  Google Scholar 

  20. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007 Mar 28;297(12):1319–31.

    CAS  PubMed  Google Scholar 

  21. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC; CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007 Oct 16;50: 1551–1560.

    CAS  PubMed  Google Scholar 

  22. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E; Studies of Left Ventricular Dysfunction. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003 Aug 20;42:705–8.

    CAS  PubMed  Google Scholar 

  23. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543–551.

    CAS  PubMed  Google Scholar 

  24. Janssens HJ, van de Lisdonk EH, Janssen M, van den Hoogen HJ, Verbeek AL. Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis 2006;65:1080–3.

    CAS  PubMed  Google Scholar 

  25. Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y. Recent diuretic use and the risk of recurrent gout attacks: The online case-crossover gout study. J Rheumatol 2006;33:1341–5.

    PubMed  Google Scholar 

  26. Braunwald E. ACE Inhibitors – A cornerstone of the treatment of heart failure. N Engl J Med 1991;325:351–353.

    CAS  PubMed  Google Scholar 

  27. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302.

    Google Scholar 

  28. Swedberg K for The CONSENSUS trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;23:1429–1435.

    Google Scholar 

  29. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geletman Em, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. results of the survival and ventricular enlargement trial (SAVE). N Engl J Med 1992;327:669–677.

    CAS  PubMed  Google Scholar 

  30. Ball SG for the AIRE investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821–828.

    Google Scholar 

  31. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670–6.

    CAS  PubMed  Google Scholar 

  32. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol 1994;23:393–400.

    CAS  PubMed  Google Scholar 

  33. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575–81.

    CAS  PubMed  Google Scholar 

  34. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431–438

    CAS  PubMed  Google Scholar 

  35. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, Kardis K, Tirologos A, Zobolos S, Pirgakis V, Anthopoulos L, Sideris D, Stamatelopoulos SF, Moulopoulos SD. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: A multicenter study. high dose enalapril study group. J Am Coll Cardiol 2000;36:2090–2095.

    CAS  PubMed  Google Scholar 

  36. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312–8.

    CAS  PubMed  Google Scholar 

  37. Poole-Wilson PA for the NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998;19:481–9.

    Google Scholar 

  38. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW 3rd, Young JB, Probstfield J. Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996;131:350–355.

    CAS  PubMed  Google Scholar 

  39. Packer M, Medina N, Yushak M. Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol 1984;3:1035–43.

    CAS  PubMed  Google Scholar 

  40. Hood WB Jr, Youngblood M, Ghali JK, Reid M, Rogers WJ, Howe D, Teo KK, LeJemtel TH. Initial blood pressure response to enalapril in hospitalized patients (Studies of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 1991 Dec 1;68(15):1465–1468.

    PubMed  Google Scholar 

  41. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678–84.

    CAS  PubMed  Google Scholar 

  42. Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J, Michelson EL, Rouleau JL, Warner Stevenson L, Swedberg K, Young JB, Yusuf S, Sellers MA, Granger CB, Califf RM, Pfeffer MA. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999;20:1182–1190.

    CAS  PubMed  Google Scholar 

  43. McDowell S, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332:1177–1181.

    CAS  PubMed  Google Scholar 

  44. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.

    CAS  PubMed  Google Scholar 

  45. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582–1587

    CAS  PubMed  Google Scholar 

  46. Dickstein K, Kjekshus J for the OPTIMAAL Study group. Effects of losartan and captopril on mortality in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002;360:752–760.

    CAS  PubMed  Google Scholar 

  47. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906.

    CAS  PubMed  Google Scholar 

  48. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003 Sep 6;362(9386):767–71.

    CAS  PubMed  Google Scholar 

  49. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002;39:463–470.

    CAS  PubMed  Google Scholar 

  50. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation 1997;96:856–863.

    CAS  PubMed  Google Scholar 

  51. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107–1114.

    CAS  PubMed  Google Scholar 

  52. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr K, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986;314:1547–1552.

    CAS  PubMed  Google Scholar 

  53. Zimmet JM, Hare JM. Nitroso-Redox interactions in the cardiovascular system. Circulation 2006;114:1531–1544.

    PubMed  Google Scholar 

  54. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel MM, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure (A-HeFT). N Engl J Med 2004;351:2049–2057.

    CAS  PubMed  Google Scholar 

  55. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher R, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–310.

    CAS  PubMed  Google Scholar 

  56. Braunwald E. ACE Inhibitors – A cornerstone of the treatment of heart failure. N Engl J Med 1991;325:351–353.

    CAS  PubMed  Google Scholar 

  57. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999;5:178–187.

    CAS  PubMed  Google Scholar 

  58. Moran AE, Cooper RS. Isosorbide and hydralazine in blacks with heart failure. N Engl J Med 2005;352:1041.

    CAS  PubMed  Google Scholar 

  59. Bibbins-Domingo K, Fernandez A. BiDil for heart failure in black patients: implications of the U.S. food and drug administration approval. Ann Intern Med 2007;146:52–56.

    PubMed  Google Scholar 

  60. Temple R, Stockbridge NL. BiDil for heart failure patients: The U.S. food and drug administration perspective. Ann Intern Med 2007;146:57–62.

    PubMed  Google Scholar 

  61. Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, Adams KF, Olukotun AY, Worcel M, Cohn JN. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007;49:32–39.

    CAS  PubMed  Google Scholar 

  62. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerzten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007:116:1555–1562.

    CAS  PubMed  Google Scholar 

  63. Behlin A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of a 5′phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008 Apri;14(3):189–97.

    Google Scholar 

  64. Guazzi M, Smaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007 Nov 27;50(22):2136–44.

    CAS  PubMed  Google Scholar 

  65. Weber K. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689–1697.

    CAS  PubMed  Google Scholar 

  66. Chhokar VS, Sun Y, Bhattacharya SK, Ashokas R, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005;111:871–878.

    CAS  PubMed  Google Scholar 

  67. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47–57.

    CAS  PubMed  Google Scholar 

  68. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–717.

    CAS  PubMed  Google Scholar 

  69. Pitt, B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;342:1309–1321.

    Google Scholar 

  70. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543–551.

    CAS  PubMed  Google Scholar 

  71. Cohn JN, TB Levine, MT Olivari, V Garberg, D Lura, GS Francis, AB Simon, and T Rector. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819.

    CAS  PubMed  Google Scholar 

  72. Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic beta-receptor antagonist. Lancet 1964;283:1080–1081.

    Google Scholar 

  73. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022–36.

    CAS  PubMed  Google Scholar 

  74. Bristow, MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558–569.

    CAS  PubMed  Google Scholar 

  75. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfield J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002;346:1357–1365.

    CAS  PubMed  Google Scholar 

  76. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569–582

    CAS  PubMed  Google Scholar 

  77. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holsclaw TL, Lukas MA. Carvedilol inhibits progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800–2806.

    CAS  PubMed  Google Scholar 

  78. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807–2816.

    CAS  PubMed  Google Scholar 

  79. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.

    CAS  PubMed  Google Scholar 

  80. Hjalmarson A, Goldstein S, Deedwania P et al. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure (MERIT-HF). JAMA 2000;283:1295–1302.

    CAS  PubMed  Google Scholar 

  81. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau J, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658

    CAS  PubMed  Google Scholar 

  82. Hjalmarson A, Goldstein S, Deedwania P et al. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure (MERIT-HF). JAMA 2000;283:1295–1302.

    CAS  PubMed  Google Scholar 

  83. Packer M, Colucci W, Shusterman NH et al. Double-blind, placebo-controlled study of carvedilol in patients with moderate to severe heart failure. Circulation 1996;94:2793–2799.

    CAS  PubMed  Google Scholar 

  84. Kowey PR. A review of carvedilol arrhythmia data in clinical trials. J Cardiovasc Phamacol Theraput 2005;10:S59-S68.

    CAS  Google Scholar 

  85. Fagerberg B et al. Effect of metoprolol CD/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–2007.

    CAS  Google Scholar 

  86. Dargie HJ, Lechat P et al. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9–13.

    Google Scholar 

  87. Eichhorn E, Domanski M; et al for the BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659–1667

    CAS  Google Scholar 

  88. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Benefifial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441–1446

    CAS  PubMed  Google Scholar 

  89. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358–65.

    CAS  PubMed  Google Scholar 

  90. Poole-Wilson PA, Swedberg K, Cleland JGF, Li Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chromic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. Lancet 2003;362:7–13

    CAS  PubMed  Google Scholar 

  91. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426–2435.

    CAS  PubMed  Google Scholar 

  92. Fang J. Angiotensin-converting enzyme inhibitors or β-blockers in heart failure: Does it matter who goes first? Circulation 2005;112:2380–2382.

    PubMed  Google Scholar 

  93. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997;79:794–798.

    CAS  PubMed  Google Scholar 

  94. Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse effects of β-blocker therapy for patients with heart failure. A quantitative overview of randomized trials. Arch Intern Med 2004;164:1389–1394.

    CAS  PubMed  Google Scholar 

  95. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendra M, Coats AJS, Fowler MB, Packer M. Effects of initiating carvedilol in patients with severe chronic heart failure. results from the COPERNICUS Study. JAMA 2003;289:712–718.

    CAS  PubMed  Google Scholar 

  96. Stevenson LW. Beta-blockers for stable heart failure. N Engl J Med 2002;346:1346–1347.

    PubMed  Google Scholar 

  97. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β-Blockers in patients with reactive airway disease: A meta-analysis. Ann Intern Med 2002;137:715–725.

    CAS  PubMed  Google Scholar 

  98. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008 Jul 15;52(3):190–9.

    CAS  PubMed  Google Scholar 

  99. Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006:98:793–795.

    PubMed  Google Scholar 

  100. Freudenberger RS, Halperin JL. Should we use anticoagulation for patients with chronic heart failure? Nat Clin Pract Cardiovasc Med 2006;3:580–581.

    PubMed  Google Scholar 

  101. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O’Connor CM, Packer M, Schulman KA, Teo K, Warren S. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004;10:113–4.

    Google Scholar 

  102. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157–64.

    CAS  PubMed  Google Scholar 

  103. Pullicino P, Thompson JLP, Barton B, Levin B, Graham S, Freudenberger RS. Warfarin Versus Aspirin in Patients with Reduced Cardiac Ejection Fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006;12:39–46.

    CAS  PubMed  Google Scholar 

  104. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007 Feb 6;115(5):576–83.

    CAS  PubMed  Google Scholar 

  105. Domanski M, Coady S, Felg J, Tian X, Sachdev V. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta Blocker Evaluation of Survival Trial [BEST]). Am J Cardiol 2007 May 15:99(10):1448–50.

    CAS  PubMed  Google Scholar 

  106. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel J, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007 Nov 29;357(22):2248–61.

    CAS  PubMed  Google Scholar 

  107. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LHM, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941–2948.

    PubMed  Google Scholar 

  108. Amabile CM, Spencer AP. Keeping your patient with heart failure safe. Arch Intern Med 2004;164:709–720.

    PubMed  Google Scholar 

  109. Kober L, Torp-Pederson C, McMurray JJ, Gotzsche O, Levy S, Crigins H, Amlie J, Carlsen J; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008 June 19:358(25):2678–87.

    Google Scholar 

  110. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in post-infarction patients with early reduction in ejection fraction. Circulation 1991;83:52–60.

    CAS  PubMed  Google Scholar 

  111. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola S. A prospective, randomized, double-blind, cross-over study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954–1961.

    CAS  PubMed  Google Scholar 

  112. Cohn, JN, Ziesche, S, Smith, R, Anand, I, Dunkman, WB, Loeb, H, Cintron, G, Boden, W, Baruch, L, Rochin, P, Loss, L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 1997;96: 856–863.

    CAS  PubMed  Google Scholar 

  113. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs. An update for clinicians: A scientific statement from the American Heart Association. Circulation 2007;115:1634–1642.

    PubMed  Google Scholar 

  114. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med 2000;160:777–784.

    CAS  PubMed  Google Scholar 

  115. Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005;294:1240–1247.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Heart Failure Service, Brigham and Women’s Hospital, Boston, MA, USA

    Neal K. Lakdawala MD

  2. Heart Failure Service, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, USA

    Akshay Desai MD

Authors
  1. Neal K. Lakdawala MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akshay Desai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Beth Israel Deaconess Medical Center, Harvard Medical School, Pilgrim Road 185, Boston, 02215, U.S.A.

    William H. Maisel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Lakdawala, N.K., Desai, A. (2010). Medical Therapy for Heart Failure. In: Maisel, W. (eds) Device Therapy in Heart Failure. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-424-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-424-7_2

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-994-9

  • Online ISBN: 978-1-59745-424-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation